Navigation Links
OmniComm Systems, Inc. Is Fueled by Another Strong Quarter Delivering Electronic Data Capture (EDC) Solutions & Services
Date:10/29/2008

Q3 2008 Contracts Total $3,970,647, up 137% Over Q3 2007

FT. LAUDERDALE, Fla., Oct. 29 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture solutions for clinical trials, today announced another momentous quarter for new business. Signed contracts through the first 3 quarters of 2008, totaling $15.8M, are exceeding projected expectations for the year.

"It is not an accident that OmniComm continues to grow and prosper in these challenging economic times," said Stephen Johnson, COO of OmniComm. "We work hard to be in tune with our customers' needs and we are steadfast in our commitment to delivering an excellent product backed by even better customer service. We are flattered by the commitment that our customers have shown to us but we must not become complacent if we are going to live up to their expectations."

Thomas Wells, Vice President of Technology for OmniComm added, "Our customers are becoming EDC experts and expect much more than just the typical data collection and cleaning. Business intelligence and integration with external applications for better data handling have become necessities for our customers to meet the challenges of their expedited clinical timelines. OmniComm's vision for early 2009 includes the creation of a Centralized Data Hub where eClinical services can be seamlessly integrated with our clients' systems and repositories. This solution will empower our clients to take control of their data and better leverage core industry standards like CDISC and CDASH."

OmniComm continues to increase its customer base with a strong mix of new customer business coupled with steady, recurring business from its existing loyal customers. The following is a breakdown of new business for Q3, 2008.

Q3 New Contracts 2008:

Industry leading academic research center and best-in-class contract research organization choose OmniComm for Technology Transitions to bring TrialMaster in-house.

Biotechnology

-- 5 month, Phase I, HIV study with 1 site and 44 subjects

-- 13 month, Phase IB, infectious disease study with 12 sites and 24

subjects

-- 4 month, Phase IV, HIV study with 30 sites and 160 subjects

-- 5 month, Phase I, infectious disease study with 1 site and 15 subjects

-- 24 month, Phase IV, hepatitis B study with 15 site and 30 subjects

-- 9 month, Phase I, infectious disease study with 1 site and 40 subjects

Contract Research Organizations

-- 30 month, Phase II, oncology study with 45 sites and 160 subjects

-- 24 month, Phase II oncology study with 8 site and subjects TBD

-- 6 month, Phase II, dermatology study with 25 sites and 200 subjects

-- 18 month, Phase II, cardiovascular study with 55 sites and 360 subjects

Medical Device

-- 15 month, study with 20 sites and 1000 subjects

-- 60 month, study with 28 sites and 225 patients

Academic

-- 18 month, Phase III, cardiovascular study with 10 sites and 60 subjects

-- 6 month, Phase I, oncology study with 25 sites and 172 patients

About OmniComm

OmniComm Systems, Inc. ( http://www.OmniComm.com ) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small- to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Chicago, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.


'/>"/>
SOURCE OmniComm Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Plexus Systems, Inc. to Exhibit at BIOMEDevice Medical Technology Conference
2. Avantis Medical Systems, Inc. Announces Key Leadership Appointments
3. CEOs Letter to Shareholders of Imaging Diagnostic Systems, Inc.
4. Concuity Announces Partnership with Financial Healthcare Systems, LLC
5. StemCor Systems, Inc. Awarded NIH SBIR Grant for Bone Marrow Aspiration Platform
6. Solei Systems, Inc., Announces That the Company Is Now Publicly Traded
7. Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R)
8. Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Brothers Movie to Be Filmed About Him
9. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
10. Cephalon Reports Another Strong Quarter
11. DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
Breaking Biology News(10 mins):